CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival
复制标题
DOI：
10.1016/s0002-9440(10)64398-2
复制
发表时间：
2002-10-01
影响因子：
6
通讯作者：
Hauptmann, S
中科院分区：
文献类型：
--
作者：
Kristiansen, G;Denkert, C;Hauptmann, S
CD24是一种糖基化程度较高的糖基化磷脂酰肌醇连接的细胞表面蛋白，在血液系统恶性肿瘤和多种实体肿瘤中均有表达。最近，芯片分析发现其在卵巢癌组织中的表达是在RNA水平上。我们用免疫组织化学方法检测了9例正常卵巢和69例卵巢上皮性肿瘤(腺瘤5例，交界性肿瘤8例，癌56例)中CD24蛋白的表达。正常卵巢和腺瘤的表面上皮细胞均不表达CD24。在交界性肿瘤中，CD24在细胞膜上的表达占75%，而胞浆表达仅在9例中1例。在浸润性卵巢癌中，84%为膜性表达，59%为胞浆表达。在所有浸润性卵巢癌的单因素生存分析中，胞浆CD24表达增加与患者生存期缩短(平均98个月与37个月，P=0.0002，对数等级检验)有非常显著的相关性。其他有意义的预后参数是国际妇产科联合会(FIGO)分期、Silverberg分级、患者年龄、未分化组织学类型和转移疾病。我们没有检测到CD24与这些临床病理参数之间的显著相关性。多因素分析显示，CD24和FIGO分期是影响预后的独立因素。我们的数据提示CD24的表达是卵巢上皮性癌患者生存时间缩短的一个新的独立分子标志物。
CD24 is a small heavily glycosylated glycosylphosphatidylinositol-linked cell surface protein, which is expressed in hematological malignancies as wen as in a large variety of solid tumors. Very recently its expression in ovarian cancer has been found on RNA level by chip analysis. We evaluated CD24 protein expression by immunohistochemistry in 9 normal ovaries and 69 epithelial ovarian tumors (5 adenomas, 8 borderline tumors, and 56 carcinomas) with known follow-up data. Surface epithelium of normal ovaries as well as adenomas did not express CD24. In borderline tumors CD24 was expressed in membrane in 75% of cases, whereas cytoplasmic expression was detected in only one of nine cases. in invasive ovarian carcinomas, a membranous expression was detected in 84% and a cytoplasmic expression in 59% of cases. In univariate survival analysis of all invasive ovarian carcinomas, a highly significant association of increased cytoplasmic CD24 expression with shortened patient survival (mean 98 months versus 37 months, P = 0.0002, log rank test) was demonstrated. other significant prognostic parameters were international Federation of Gynecology and Obstetrics (FIGO) stage, Silverberg grade, patient age, undifferentiated histological type, and metastatic disease. We did not detect a significant correlation of CD24 with these clinicopathological parameters. In multivariate analysis, only CD24 and FIGO stage were independent prognostic parameters. Our data suggest that the expression of CD24 as detected by inummohistochemistry is a new independent molecular marker for shortened survival time of patients with epithelial ovarian carcinomas.